Duality Advisers LP Raises Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Duality Advisers LP lifted its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 431.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,564 shares of the medical research company's stock after purchasing an additional 6,953 shares during the period. Duality Advisers LP's holdings in Bio-Rad Laboratories were worth $2,765,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. ING Groep NV bought a new position in Bio-Rad Laboratories in the third quarter worth about $44,000. Ronald Blue Trust Inc. lifted its holdings in Bio-Rad Laboratories by 241.4% in the third quarter. Ronald Blue Trust Inc. now owns 338 shares of the medical research company's stock worth $128,000 after acquiring an additional 239 shares during the last quarter. Signaturefd LLC raised its holdings in shares of Bio-Rad Laboratories by 15.8% during the fourth quarter. Signaturefd LLC now owns 352 shares of the medical research company's stock valued at $114,000 after buying an additional 48 shares during the last quarter. Banque Cantonale Vaudoise raised its holdings in shares of Bio-Rad Laboratories by 25.0% during the third quarter. Banque Cantonale Vaudoise now owns 375 shares of the medical research company's stock valued at $135,000 after buying an additional 75 shares during the last quarter. Finally, First Eagle Investment Management LLC raised its holdings in shares of Bio-Rad Laboratories by 139.8% during the third quarter. First Eagle Investment Management LLC now owns 458 shares of the medical research company's stock valued at $164,000 after buying an additional 267 shares during the last quarter. Institutional investors own 65.24% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on BIO. Royal Bank of Canada cut their price target on Bio-Rad Laboratories from $484.00 to $480.00 and set an "outperform" rating on the stock in a report on Friday, February 16th. Citigroup cut Bio-Rad Laboratories from a "buy" rating to a "neutral" rating and cut their price target for the company from $400.00 to $365.00 in a report on Wednesday, April 3rd. StockNews.com cut Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Friday, April 5th. Finally, UBS Group lifted their price target on Bio-Rad Laboratories from $395.00 to $420.00 and gave the company a "buy" rating in a report on Friday, February 16th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Bio-Rad Laboratories currently has an average rating of "Moderate Buy" and an average target price of $468.00.

Insiders Place Their Bets

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 3,000 shares of Bio-Rad Laboratories stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $336.00, for a total value of $1,008,000.00. Following the transaction, the executive vice president now owns 6,942 shares in the company, valued at $2,332,512. The transaction was disclosed in a document filed with the SEC, which is available at this link. 17.06% of the stock is currently owned by company insiders.

Bio-Rad Laboratories Price Performance

Shares of NYSE BIO traded up $0.18 during mid-day trading on Monday, reaching $279.91. 217,079 shares of the company traded hands, compared to its average volume of 203,054. Bio-Rad Laboratories, Inc. has a fifty-two week low of $261.59 and a fifty-two week high of $473.50. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.83 and a quick ratio of 4.34. The firm has a market cap of $7.98 billion, a PE ratio of -13.03 and a beta of 0.87. The stock has a fifty day simple moving average of $328.92 and a 200-day simple moving average of $319.24.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings results on Thursday, February 15th. The medical research company reported $3.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.17. The firm had revenue of $681.18 million for the quarter, compared to analyst estimates of $685.00 million. Bio-Rad Laboratories had a negative net margin of 23.86% and a positive return on equity of 3.90%. The firm's quarterly revenue was down 6.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.31 earnings per share. Equities research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.41 EPS for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.